Literature DB >> 8155342

Phasic coronary flow characteristics in patients with hypertrophic cardiomyopathy: a study by coronary Doppler catheter.

T Akasaka1, J Yoshikawa, K Yoshida, K Maeda, T Takagi, S Miyake.   

Abstract

Abnormal patterns of coronary flow velocity have been observed in patients with symmetric left ventricular hypertrophy in conditions such as aortic stenosis and systemic hypertension. However, phasic coronary flow characteristics have not been investigated in patients with asymmetric left ventricular hypertrophy in hypertrophic cardiomyopathy. The purpose of this study was to assess phasic coronary flow characteristics and their relation to echocardiographic and hemodynamic parameters in patients with hypertrophic cardiomyopathy. Coronary flow velocity was recorded in the left anterior descending artery with a 20 MHz Doppler catheter in eight patients with hypertrophic nonobstructive cardiomyopathy and eight control subjects with normal coronary arteries. Flow reversals observed in systole in all patients with hypertrophic cardiomyopathy, and the time velocity integrals of systolic flow were significantly smaller in patients with hypertrophic cardiomyopathy than in control subjects (-1.5 +/- 1.7 versus 4.3 +/- 1.2 cm; p < 0.01). The time from the beginning of diastole to peak diastolic velocity corrected by the square root of R-R interval (square root of RR) was prolonged significantly, and the velocity half-time from peak diastolic velocity corrected by square root of RR was shorter in the patients with hypertrophic cardiomyopathy compared with those in the control subjects (6.8 +/- 2.0 msec versus 4.0 +/- 0.6 msec [p < 0.01] and 9.2 +/- 4.9 msec versus 13.9 +/- 2.0 msec [p < 0.05], respectively). Peak velocity and time velocity integral of flow reversal showed significant correlations with anterior ventricular septal thickness (y = -0.5x + 13.5, r = 0.8, and p < 0.01; y = -1.3 +/- 16.8, r = 0.8, and p = 0.024, respectively), the septal/free wall thickness ratio (y = -0.1x + 1.1, r = 0.8, and p < 0.01; y = -0.2x + 1.4, r = 0.9, and p < 0.01, respectively), and the degree of narrowing of the first septal perforator arteries (y = 1.9x + 91.6, r = 0.8, and p = 0.012; y = 6.1x + 80.6, r = 0.9, and p < 0.01, respectively). In conclusion, flow reversal in systole and slow acceleration and rapid deceleration in diastole were characteristics in patients with hypertrophic cardiomyopathy. Flow reversal might be related to the degree of left ventricular asymmetry and compression of the septal perforator arteries.

Entities:  

Mesh:

Year:  1994        PMID: 8155342     DOI: 10.1016/s0894-7317(14)80413-6

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  10 in total

1.  Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy.

Authors:  J J Crowley; P S Dardas; A A Harcombe; L M Shapiro
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

2.  Intramyocardial coronary flow characteristics in patients with hypertrophic cardiomyopathy: non-invasive assessment by transthoracic Doppler echocardiography.

Authors:  N Watanabe; T Akasaka; Y Yamaura; M Akiyama; S Kaji; Y Saito; K Yoshida
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

3.  Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics.

Authors:  M J Kofflard; M Michels; R Krams; M Kliffen; M L Geleijnse; F J Ten Cate; P W Serruys
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

4.  Diastolic flow velocity pattern of the left anterior descending coronary artery in hypertrophied heart, with special reference to the difference between hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy.

Authors:  Nobuo Fukuda; Yamato Fukuda; Satofumi Morishita; Koichi Sakabe; Hisanori Shinohara; Yoshiyuki Tamura
Journal:  J Echocardiogr       Date:  2010-01-13

5.  Systolic compression of epicardial coronary and intramural arteries in children with hypertrophic cardiomyopathy.

Authors:  Saidi A Mohiddin; Lameh Fananapazir
Journal:  Tex Heart Inst J       Date:  2002

6.  Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy.

Authors:  P Petkow Dimitrow; M Krzanowski; R Nizankowski; A Szczeklik; J S Dubiel
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

7.  Validation of high temporal resolution spiral phase velocity mapping of temporal patterns of left and right coronary artery blood flow against Doppler guidewire.

Authors:  Jennifer Keegan; Claire E Raphael; Kim Parker; Robin M Simpson; Stephen Strain; Ranil de Silva; Carlo Di Mario; Julian Collinson; Rod H Stables; Ricardo Wage; Peter Drivas; Malindie Sugathapala; Sanjay K Prasad; David N Firmin
Journal:  J Cardiovasc Magn Reson       Date:  2015-10-02       Impact factor: 5.364

8.  Longitudinal hemodynamic measurements in swine heart failure using a fully implantable telemetry system.

Authors:  Jenny S Choy; Zhen-Du Zhang; Koullis Pitsillides; Margo Sosa; Ghassan S Kassab
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

9.  Predominant location of coronary artery atherosclerosis in the left anterior descending artery. The impact of septal perforators and the myocardial bridging effect.

Authors:  Jarosław Wasilewski; Jacek Niedziela; Tadeusz Osadnik; Agata Duszańska; Wojciech Sraga; Piotr Desperak; Jolanta Myga-Porosiło; Zuzanna Jackowska; Andrzej Nowakowski; Jan Głowacki
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-12-30

10.  Echocardiographic and hemodynamic determinants of right coronary artery flow reserve and phasic flow pattern in advanced non-ischemic cardiomyopathy.

Authors:  Pedro Graziosi; Barbara Ianni; Expedito Ribeiro; Marco Perin; Leonardo Beck; Claudio Meneghetti; Charles Mady; Eulogio Martinez Filho; Jose A F Ramires
Journal:  Cardiovasc Ultrasound       Date:  2007-09-26       Impact factor: 2.062

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.